ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
13.50
-1.37 (-9.21%)
Aug 22, 2025, 4:00 PM - Market closed
ARS Pharmaceuticals Analyst Ratings
Total Analysts
4
Consensus Rating
Strong Buy
Price Target
$28.75
Upside
+112.96%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Initiates $30 | Buy | Initiates | $30 | +122.22% | Mar 7, 2025 |
| Raymond James | Raymond James | Strong Buy Maintains $26 → $28 | Strong Buy | Maintains | $26 → $28 | +107.41% | Jan 14, 2025 |
| Leerink Partners | Leerink Partners | Buy Maintains $26 → $27 | Buy | Maintains | $26 → $27 | +100.00% | Jan 13, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 | Buy | Reiterates | $30 | +122.22% | Oct 8, 2024 |
| Leerink Partners | Leerink Partners | Buy Maintains $21 → $25 | Buy | Maintains | $21 → $25 | +85.19% | Sep 20, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 | Buy | Reiterates | $30 | +122.22% | Sep 16, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $30 | Buy | Reiterates | $30 | +122.22% | Sep 9, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $30 | Buy | Initiates | $30 | +122.22% | Aug 20, 2024 |
| Raymond James | Raymond James | Buy → Strong Buy Upgrades $18 → $22 | Buy → Strong Buy | Upgrades | $18 → $22 | +62.96% | Aug 13, 2024 |
| Raymond James | Raymond James | Buy Initiates $18 | Buy | Initiates | $18 | +33.33% | Jul 25, 2024 |
| Wedbush | Wedbush | Buy Reiterates $19 | Buy | Reiterates | $19 | +40.74% | Mar 11, 2024 |
| Leerink Partners | Leerink Partners | Hold → Buy Upgrades $6 → $18 | Hold → Buy | Upgrades | $6 → $18 | +33.33% | Mar 5, 2024 |
| Wedbush | Wedbush | Buy Maintains $5 → $13 | Buy | Maintains | $5 → $13 | -3.70% | Nov 13, 2023 |
| Wedbush | Wedbush | Buy Maintains $15 → $5 | Buy | Maintains | $15 → $5 | -62.96% | Sep 21, 2023 |
| William Blair | William Blair | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Sep 20, 2023 |
| Wedbush | Wedbush | Buy Reiterates $15 | Buy | Reiterates | $15 | +11.11% | Aug 14, 2023 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.